跳至主要内容
临床试验/NCT04503434
NCT04503434已完成不适用

Patients' Experiences in a Medicalized Hotel for COVID-19 Acute Care Support

Hospital Clinic of Barcelona1 个研究点 分布在 1 个国家目标入组 517 人开始时间: 2020年5月15日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
517
试验地点
1
主要终点
The Picker Patient Experience Questionnaire

研究概览

简要总结

The 11th March 2020, the World Health Organization (WHO) declared the novel coronavirus Covid-19 as a pandemic. Urgent reorganization was required to give answers to the needs of this new illness. Since mid March, the number of patients admitted every day grew exponentially, and despite strengthening the Home Hospitalization service, resources were insufficient to care for such a number of people at home. The HH was called to transform a hotel into a medicalized healthcare space.

Current health policy emphasizes on patient experience, as one of the key components of quality of care. Analyzing patients experience will provide knowledge about their authentic concerns or what they identify as real needs, how they perceive the care received and will allow finding out if it was a good alternative. Patients must be involved in decision-making about their heath situation and treatment in order to provide an integrated healthcare.

Aims: To assess the patient experience during hospital admission in a Medicalized Hotel for COVID-19, from 8th March to 25th May, and variables that may influence these experiences.

Study type: Observational and descriptive study with a cross-sectional design. The study population consisted of patients admitted in Medicalized Hotel who met inclusion criteria.

Sample size: 517 patients. Main variable: Patient experience (collected by the Picker Patient Experience questionnaire, PPE-15, translated to Catalan and Spanish), that content four open questions analyzed in a qualitative way. Other variables: Socio-demographic and review clinical records.

详细描述

The current pandemic caused by the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) demands urgent reorganization. Hospital multidisciplinary and departmental collaboration was required to work on all the principles of overvoltage capacity, including: new space definition; provision's resources; staff recruitment; and ad hoc training. Likewise, assistant protocols suffered continuous modifications to deal with this new situation.

Catalonia is one of the 17 autonomous communities of Spain and it has been granted global competencies in the area of healthcare. The Catalan healthcare model is a multi-provider one integrated in a unique public network. The organization is structured in four integrated health areas, one of which is the Integrated Health Area of Barcelona Esquerra (Área Integral de Salud de Barcelona Esquerra - AIS-BE), caring for a population of 524,000 inhabitants, representing 35% of the population of Barcelona. The territory referred to this study, includes the Hospital Clinic as reference center, two general hospitals and 19 primary care centers. The Hospital Clínic -a tertiary university hospital- is a public institution with a long reputation of excellence in care provision, training and research at national and international level.

The management of the Hospital Clinic worked on a contingency plan, at internal and territorial level, together with the Health Department of the Generalitat de Catalunya. For the internal contingency plan to deal with the pandemic, different committees were created. Two of them were the Technical /Operational Committee and the ICU Committee. The technical committee included the Departments of Internal Medicine, Infections, Pneumology, Microbiology and all the medical and surgical departments with ICUs, occupational health, and the transversal Home Hospitalization Unit (HH) to maximize cooperation among professionals, levels of care and institutions. Hospital-at-home is defined as the service in charge of providing active treatment by health care professionals, in patient's house, for a condition that otherwise would require traditional hospitalization for a limited period of time (8). Hospital-at-home is a safe and cost effectiveness service, and has become a popular response to the increasing demand for acute hospital beds.

The idea of transforming a hotel into a healthcare facility wanted to solve three needs: a) grouping patients who required HH, b) providing more beds (offering intermediate care to patients who didn't require critical care) and c) allowing the isolation of people who cannot do it at home.

This paper consists in an observational and descriptive study with a cross-sectional design, in which we analyze patients' experience during admission in a Medicalized Hotel using a validate survey.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Cross Sectional

入排标准

性别
All
接受健康志愿者

入选标准

  • All patients admitted in Medicalized Hospital who agreed to participate in the study.

排除标准

  • Not localized, language barrier, dementia.

结局指标

主要结局

The Picker Patient Experience Questionnaire

时间窗: one month

An adapted shorter version of The Picker Patient Experience Questionnaire, validated into Spanish and Catalan was used to identify whether exist any problem in the healthcare provided. It consists of 15 questions distributed to eight dimensions of care: respect, coordination, information/communication/education, physical comfort, emotional support, involvement of relatives, transition and continuity and finally overall impression. The questions have from two ("yes" or "no") responses to four answer options ("yes", "yes, to some extend", "no" or "I didn't need to"). Neutral answers, such as "I did not need to", and the most positive answer are coded as a "non-problem" (score = 0). The remaining responses are coded as "problems" (score = 1). The PPE-15 has previously been found to be valid and reliable.

次要结局

  • Open questions(one month)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Carme Hernandez

Director of Home Hospitalization unit and Coordinator of Medicalitzed-Hotel

Hospital Clinic of Barcelona

研究点 (1)

Loading locations...

相似试验

进行中(未招募)
不适用
Multinational Clinical Trial of 12 weeks of duration to test the efficacy of a new drug called CHF 1535 50/6 (fixed combination of a corticoteroid and a long-acting Beta 2 agonist) compared to a free combination of the same substances, and to the corticosteroid only in asthmatic childreAsthma
EUCTR2009-016757-18-ITCHIESI1,000
进行中(未招募)
不适用
Multinational Clinical Trial of 12 weeks of duration to test the efficacy of a new drug called CHF 1535 50/6 (fixed combination of a corticoteroid and a long-acting Beta 2 agonist) compared to a free combination of the same substances, and to the corticosteroid only in asthmatic childreMedDRA version: 14.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthma
EUCTR2009-016757-18-HUChesi Farmaceutici SpA700
进行中(未招募)
1 期
Multinational Clinical Trial of 12 weeks of duration to test the efficacy of a new drug called CHF 1535 50/6 (fixed combination of a corticoteroid and a long-acting Beta 2 agonist) compared to a free combination of the same substances, and to the corticosteroid only in asthmatic childreAsthmaMedDRA version: 14.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
EUCTR2009-016757-18-SKChesi Farmaceutici SpA700
进行中(未招募)
不适用
Multinational Clinical Trial of 12 weeks of duration to test the efficacy of a new drug called CHF 1535 50/6 (fixed combination of a corticoteroid and a long-acting Beta 2 agonist) compared to a free combination of the same substances, and to the corticosteroid only in asthmatic childreasthma
EUCTR2009-016757-18-Outside-EU/EEAChiesi Farmaceutici SpA700
进行中(未招募)
1 期
Multinational Clinical Trial of 12 weeks of duration to test the efficacy of a new drug called CHF 1535 50/6 (fixed combination of a corticoteroid and a long-acting Beta 2 agonist) compared to a free combination of the same substances, and to the corticosteroid only in asthmatic childreMedDRA version: 14.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthma
EUCTR2009-016757-18-FRChiesi Farmaceutici SpA700